Direxion mRNA ETF
MSGR
MSGR was delisted on the 21st of April, 2023.
2 hedge funds and large institutions have $198K invested in Direxion mRNA ETF in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
39% less capital invested
Capital invested by funds: $323K → $198K (-$124K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$116K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citigroup
New York
| $196K | -$116K | -7,964 | -35% |
|
|
2
UBS Group
Zurich,
Switzerland
| $2.27K | +$2.47K | +170 | New |
|
MSGR Hedge Fund Activity: Q1 2023 in Review
2 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Direxion mRNA ETF (MSGR) for Q1 2023, worth a combined $198K — down 39% from $323K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new MSGR positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $2.47K. The largest seller was Citigroup, cutting an estimated $116K.
- 2 institutional investors held Direxion mRNA ETF (MSGR) as of Q1 2023, up from 1 in Q4 2022.
- Funds reported $198K of Direxion mRNA ETF stock for Q1 2023, down 39% quarter-over-quarter.
- 1 fund opened new Direxion mRNA ETF positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest Direxion mRNA ETF buyer in Q1 2023 was UBS Group, an estimated $2.47K added.
- The largest Direxion mRNA ETF seller in Q1 2023 was Citigroup, an estimated $116K sold.
Based on aggregated 13F filings for Q1 2023.